Economic impact of a triptan Rx-to-OTC switch in six EU countries.
about
Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison.From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.The value of self-medication: summary of existing evidence.
P2860
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@ast
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@en
type
label
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@ast
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@en
prefLabel
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@ast
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@en
P2093
P2860
P1433
P1476
Economic impact of a triptan Rx-to-OTC switch in six EU countries.
@en
P2093
Aurelie Millier
Joshua Cohen
Mondher Toumi
P2860
P304
P356
10.1371/JOURNAL.PONE.0084088
P407
P577
2013-12-19T00:00:00Z